Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) EBIT Margin (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed EBIT Margin for 13 consecutive years, with 399.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 39950.0% year-over-year to 399.71%, compared with a TTM value of 25.93% through Dec 2025, down 1538.0%, and an annual FY2025 reading of 2368.24%, up 237879.0% over the prior year.
  • EBIT Margin was 399.71% for Q4 2025 at Tandem Diabetes Care, down from 9.17% in the prior quarter.
  • Across five years, EBIT Margin topped out at 6.07% in Q4 2021 and bottomed at 399.71% in Q4 2025.
  • Average EBIT Margin over 5 years is 34.67%, with a median of 12.28% recorded in 2024.
  • The sharpest move saw EBIT Margin soared 5372bps in 2024, then plummeted -39950bps in 2025.
  • Year by year, EBIT Margin stood at 6.07% in 2021, then plummeted by -233bps to 8.06% in 2022, then tumbled by -121bps to 17.82% in 2023, then soared by 99bps to 0.21% in 2024, then tumbled by -194019bps to 399.71% in 2025.
  • Business Quant data shows EBIT Margin for TNDM at 399.71% in Q4 2025, 9.17% in Q3 2025, and 21.53% in Q2 2025.